Lung Cancer Dispatch
4.5K views | +0 today
Follow
Lung Cancer Dispatch
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Scooped by Cancer Commons
Scoop.it!

Necitumumab Plus Chemotherapy Shows Overall Survival Benefit in Patients With Squamous NSCLC

Necitumumab Plus Chemotherapy Shows Overall Survival Benefit in Patients With Squamous NSCLC | Lung Cancer Dispatch | Scoop.it

"A large phase III study investigating necitumumab (IMC-11F8) in combination with gemcitabine and cisplatin as first-line treatment for advanced squamous non–small cell lung cancer show a statistically significant improvement in overall survival of patients with stage IV disease.


"Patients receiving necitumumab plus chemotherapy had a median survival of 11.5 months compared to 9.9 months for patients treated with chemotherapy alone.


"Progression-free survival and disease control rate were also significantly improved."


Editor's note: This story is about a clinical trial that is testing the effectiveness of a new treatment for lung cancer patients. So far, the trial has found that the treatment is promising for people with stage IV squamous non-small cell lung cancer (NSCLC). To learn more about clinical trials, and the risks and advantages for patients who participate in them, click here.

Cancer Commons's insight:

The ASCO Post  |  May 16, 2014

more...
No comment yet.
Scooped by Cancer Commons
Scoop.it!

Lilly's Necitumumab Improves Overall Survival In Largest Ever Phase III Study In First-Line Treatment Of Stage IV Squamous Non-Small Cell Lung Cancer

Lilly's Necitumumab Improves Overall Survival In Largest Ever Phase III Study In First-Line Treatment Of Stage IV Squamous Non-Small Cell Lung Cancer | Lung Cancer Dispatch | Scoop.it

"Lung cancer patients with metastatic squamous cell carcinoma have seen few treatment advancements over the last two decades, leaving these patients with a poor prognosis. This is in contrast to the progress seen in nonsquamous non-small cell lung cancer (NSCLC). Results from the largest ever Phase III trial in first-line squamous NSCLC announced by Eli Lilly and Company (NYSE: LLY) today provide the first detailed look at a potential new treatment option for these patients."


Editor's note: This story is about a clinical trial that found promising results for some lung cancer patients treated with the new targeted therapy drug necitumumab. Necitumumab appears to benefit some patients with stage IV squamous non-small cell lung cancer (NSCLC).

Cancer Commons's insight:

The Wall Street Journal  |  May 14, 2014

more...
No comment yet.